Patients’ own autoantibodies may hold key to boosting cancer immunotherapy response

A new study has revealed that autoantibodies—immune proteins traditionally associated with autoimmune disease—may profoundly influence how cancer patients respond to immunotherapy.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup